Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TERRENCE C KEANEY

Allopathic & Osteopathic Physicians Dermatology

NPI
1902049489
CMS profile
176391
Location
WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$112,996.35

101 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Allergan, Inc. $89,570.70 76
MERZ NORTH AMERICA, INC. $23,116.72 17
Janssen Biotech, Inc. $113.26 2
SUN PHARMACEUTICAL INDUSTRIES INC. $95.63 1
AbbVie Inc. $27.84 1
Incyte Corporation $23.97 1
GENZYME CORPORATION $23.63 1
Almirall LLC $13.42 1
Lilly USA, LLC $11.18 1

Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TERRENCE C KEANEY

NPI 1902049489 · CMS profile ID 176391

Allopathic & Osteopathic Physicians / Dermatology

WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1902049489?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TERRENCE C KEANEY, NPI 1902049489, CMS profile ID 176391. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902049489?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). TERRENCE C KEANEY, NPI 1902049489, CMS profile ID 176391. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902049489?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
TERRENCE C KEANEY, NPI 1902049489, CMS profile ID 176391, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1902049489?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

101 matching records · $112,996.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 101 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–101 of 101.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan, Inc. $650.0001/19/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792829929 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $73,801.47 120
PY2020 $65,541.59 33
PY2021 $112,996.35 101
PY2022 $225,403.41 126
PY2023 $323,625.99 181
PY2024 $134,810.52 85
PY2025 $183,693.66 118

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $472.44 4
PY2025 Principal investigator $639,349.76 47
PY2024 Recipient $1,049.44 4
PY2024 Principal investigator $297,232.11 28
PY2023 Principal investigator $627,245.79 28
PY2022 Recipient $6,300.00 1
PY2022 Principal investigator $157,230.87 20
PY2021 Principal investigator $94,270.09 21
PY2020 Principal investigator $197,305.18 56
PY2019 Principal investigator $314,051.72 42

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $8,551.23 12/31/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Prospective, Open-Label Study to Evaluate Subject Satisfaction with Overall Facial Appearance After Treatment with JUVeDERM Products in Medical Weight Loss (MWL) Subjects No dispute reported 06/30/2026 1202533635
Principal investigator 1 ABBVIE INC. $2,177.82 12/31/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Phase 1 Study to Evaluate the Safety and Efficacy of Co-administration of AGN-151586 and BOTOX in Subjects for Treatment of Glabellar Lines (GL) No dispute reported 06/30/2026 1202533637
Principal investigator 1 ABBVIE INC. $10,083.36 12/31/2025 Non-covered Recipient Entity
SKIN DC PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study No dispute reported 06/30/2026 1202533639
Principal investigator 1 ABBVIE INC. $2,837.50 12/18/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202531206
Principal investigator 1 ABBVIE INC. $3,035.00 12/17/2025 Non-covered Recipient Entity
SKIN DC PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202530996
Principal investigator 1 ABBVIE INC. $3,687.50 12/16/2025 Non-covered Recipient Entity
SKIN DC PLLC
A multicenter, double-blind, randomized, parallel-group, controlled study to evaluate the safety and effectiveness of ELAPR002f injectable gel in adult participants with atrophic acne scars No dispute reported 06/30/2026 1202530600
Principal investigator 1 ABBVIE INC. $2,571.75 12/04/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System No dispute reported 06/30/2026 1202527892
Principal investigator 1 ABBVIE INC. $500.00 11/13/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202524121
Principal investigator 1 ABBVIE INC. $20,782.95 11/13/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202524161
Principal investigator 1 ABBVIE INC. $10,267.50 11/13/2025 Non-covered Recipient Entity
SKIN DC PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202524163
Principal investigator 1 ABBVIE INC. $54,308.37 11/05/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System No dispute reported 06/30/2026 1202522123
Principal investigator 1 ABBVIE INC. $10,000.00 10/16/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Evaluate the Safety and Effectiveness of JUVEDERM Products in Adult Participants for the Change of Their Overall Facial Appearance No dispute reported 06/30/2026 1202517125
Principal investigator 1 ABBVIE INC. $13,602.12 10/16/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202517283
Principal investigator 1 ABBVIE INC. $2,975.00 10/16/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202517285
Principal investigator 1 ABBVIE INC. $11,696.25 10/15/2025 Non-covered Recipient Entity
SKIN DC PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202516981
Principal investigator 1 ABBVIE INC. $1,865.31 10/09/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System No dispute reported 06/30/2026 1202515711
Recipient ABBVIE INC. $271.92 10/04/2025 Covered Recipient Physician A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars No dispute reported 06/30/2026 1202399259
Recipient ABBVIE INC. $53.69 10/04/2025 Covered Recipient Physician A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars No dispute reported 06/30/2026 1202399263
Recipient ABBVIE INC. $21.48 10/04/2025 Covered Recipient Physician A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars No dispute reported 06/30/2026 1202399266
Recipient ABBVIE INC. $125.35 10/03/2025 Covered Recipient Physician A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars No dispute reported 06/30/2026 1202399254
Principal investigator 1 ABBVIE INC. $271.14 09/25/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System No dispute reported 06/30/2026 1202512366
Principal investigator 1 ABBVIE INC. $13,602.12 09/19/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202511660
Principal investigator 1 ABBVIE INC. $5,137.50 09/19/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202511662
Principal investigator 1 ABBVIE INC. $15,893.75 09/18/2025 Non-covered Recipient Entity
SKIN DC PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202511528
Principal investigator 1 ABBVIE INC. $9,500.00 09/04/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System No dispute reported 06/30/2026 1202509460
Principal investigator 1 ABBVIE INC. $3,471.46 08/14/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202504587
Principal investigator 1 ABBVIE INC. $15,556.25 08/14/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202504589
Principal investigator 1 ABBVIE INC. $73,512.45 08/14/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202504731
Principal investigator 1 ABBVIE INC. $24,466.25 08/14/2025 Non-covered Recipient Entity
SKIN DC PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504755
Principal investigator 1 ABBVIE INC. $317.98 08/06/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202502989
Principal investigator 1 ABBVIE INC. $393.51 07/18/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202498926
Principal investigator 1 ABBVIE INC. $7,281.25 07/17/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202498514
Principal investigator 1 ABBVIE INC. $72,367.05 07/17/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202498774
Principal investigator 1 ABBVIE INC. $18,573.75 07/16/2025 Non-covered Recipient Entity
SKIN DC PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202498466
Principal investigator 1 ABBVIE INC. $5,992.00 06/17/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202491747
Principal investigator 1 ABBVIE INC. $12,581.25 06/17/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202491767
Principal investigator 1 ABBVIE INC. $6,526.56 06/13/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202491419
Principal investigator 1 ABBVIE INC. $21,856.25 06/12/2025 Non-covered Recipient Entity
SKIN DC PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202491147
Principal investigator 1 ABBVIE INC. $2,208.80 06/04/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administration of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Upper Facial Lines (Glabellar Lines Lateral Canthal Lines and Forehead Lines) No dispute reported 06/30/2026 1202490055
Principal investigator 1 ABBVIE INC. $25,223.75 05/16/2025 Non-covered Recipient Entity
SKIN DC PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202485285
Principal investigator 1 ABBVIE INC. $23,312.50 05/16/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202485377
Principal investigator 1 ABBVIE INC. $4,000.00 05/07/2025 Non-covered Recipient Entity
SKINDC PLLC
A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence No dispute reported 06/30/2026 1202482327
Principal investigator 1 ABBVIE INC. $8,262.50 04/17/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202477449
Principal investigator 1 ABBVIE INC. $19,508.75 04/16/2025 Non-covered Recipient Entity
SKIN DC PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202476930
Principal investigator 1 ABBVIE INC. $3,757.60 03/24/2025 Non-covered Recipient Entity
SKIN DC PLLC
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin- Adult Participants With Glabellar Lines No dispute reported 06/30/2026 1202465483
Principal investigator 1 ABBVIE INC. $283.31 03/14/2025 Non-covered Recipient Entity
SKIN DC PLLC
M24-704 - A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVEDERM Products, KYBELLA, CoolSculpting Elite and SkinMedica Products (US Harmony) No dispute reported 06/30/2026 1202463853
Principal investigator 1 ABBVIE INC. $24,035.00 03/13/2025 Non-covered Recipient Entity
SKIN DC PLLC
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202463152
Principal investigator 1 ABBVIE INC. $27,480.00 02/13/2025 Non-covered Recipient Entity
SKIN DC PLLC
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202450964
Principal investigator 1 ABBVIE INC. $2,000.00 02/06/2025 Non-covered Recipient Entity
SKIN DC PLLC
M22-974 - A Prospective Multi-center Open-label Study to Evaluate Subject Satisfaction and Natural Outcomes Following Administration of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Upper Facial Lines (Glabellar Lines Lateral Canthal Lines and Forehead Lines) No dispute reported 06/30/2026 1202447016
Principal investigator 1 ABBVIE INC. $1,130.37 01/24/2025 Non-covered Recipient Entity
SKIN DC PLLC
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202441152
Principal investigator 1 ABBVIE INC. $31,905.00 01/16/2025 Non-covered Recipient Entity
SKIN DC PLLC
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202439092